Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the 13 Best Healthcare Stocks to Buy Under $10. In a report released on July 7, Luca Issi from RBC Capital maintained a Buy rating on Dyne Therapeutics, ...

Announcing a new publication for Acta Materia Medica journal. Bioresponsive materials have gained prominence as innovative ...

HBO is a network built on quality content. The following series are no exception to that rule, but each deserves a larger audience.

Fully cell-free process aims to democratize personalized cancer therapeutics with shorter turnaround and negligible bioburden ...

Gene therapeutic strategies for peripheral artery disease. Neovascularization in ischemic limbs may be achieved by transducing vascular endothelium directly with viral-delivered transgenes or ncRNA ...

In parallel, e-therapeutics has successfully completed GMP manufacturing of the clinical batch of ETX-312, supporting the Company’s operational readiness to progress to first-in-human dosing.

Understanding the duration of partial hospitalization programs (PHP) is crucial for patients and providers alike. The length ...

Recent developments in protein-protein interactions (PPI) give hope for patients with advanced or untreatable diseases.